Deepnoid, Largest and Second-Largest Shareholders Participate on First Day of Rights Offering Subscription for Existing Shareholders

Deepnoid, a leading first-generation medical artificial intelligence (AI) company in Korea, announced on December 8 that on the first day of the rights offering subscription for existing shareholders, CEO Choi Woosik, the largest shareholder, and Executive Director Kim Taegyu, the second-largest shareholder, fully subscribed to their allotted shares.

By immediately completing their subscriptions within the allocated range, they reaffirmed their commitment to responsible management. A company representative explained, "With the proactive participation of the largest and second-largest shareholders, a stable foundation has been established for the rights offering to proceed smoothly."

The final issue price for the rights offering is 2,885 KRW per share, and subscriptions for existing shareholders will continue until December 9. Subsequently, from December 11 to 12, a public offering for forfeited shares will take place, with payment due on December 16. The new shares will be listed on December 30.

Through this rights offering, Deepnoid plans to further strengthen its strategy of selection and concentration on core medical AI products while improving its financial structure. The company’s main medical AI products include: ▲ M4CXR, a generative AI-based chest X-ray interpretation solution ▲ DEEP:NEURO, an AI-assisted diagnostic solution for cerebral aneurysm detection ▲ DEEP:CHEST, a real-time multi-pulmonary disease detection and diagnostic assistance solution. Deepnoid plans to invest in regulatory approval, clinical trials, data acquisition, and commercialization of its Tele-Radiology Service (TRS).

Deepnoid’s M4CXR completed clinical trials after receiving Investigational New Drug (IND) approval in August. The product is currently undergoing regulatory approval procedures with the Ministry of Food and Drug Safety. Last month, it was designated as an innovative medical device in the advanced technology category (No. 119) by the Ministry, recognizing its technological innovation.

Following the rights offering, Deepnoid will concretize its service business model based on M4CXR and expand collaborations with medical institutions and tele-radiology centers. Through these efforts, the company aims to strengthen its competitiveness in the medical AI market and secure a foundation for mid- to long-term growth.

Choi Woosik, CEO of Deepnoid, stated, "As the largest shareholder, I have more confidence than anyone in the company's future strategy and technological competitiveness," adding, "Even in this subscription, I participated responsibly within a realistic range, and based on the funds raised, we will proceed without delay with regulatory approval and commercialization of our core products."

This content was produced with the assistance of AI translation services.